

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l5 sss full
FULL SEARCH INITIATED 16:07:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11522 TO ITERATE

100.0% PROCESSED 11522 ITERATIONS 37 ANSWERS
SEARCH TIME: 00.00.01

L7 37 SEA SSS FUL L5

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	367.09	367.30

FILE 'STNGUIDE' ENTERED AT 16:07:44 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	367.48

FILE 'HCAPLUS' ENTERED AT 16:09:29 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 1 Feb 2008 VOL 148 ISS 6
FILE LAST UPDATED: 31 Jan 2008 (20080131/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l7

L8          539 L7

=> s (fine line) or wrinkle

         327807 FINE
         729587 LINE
           1027 FINE LINE
                  (FINE(W)LINE)
           7901 WRINKLE
L9         8923 (FINE LINE) OR WRINKLE

=> s l8 and l9

L10           8 L8 AND L9

=> s l10 and (PY<2004 or AY<2004 or PRY<2004)

       23975504 PY<2004
        4760001 AY<2004
        4238501 PRY<2004
L11           5 L10 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   2.69     370.17

FILE 'STNGUIDE' ENTERED AT 16:09:35 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> d l11 1-5 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y
```

L11 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Film forming foamable pharmaceutical and cosmetic compositions and cosmetic and therapeutic uses thereof

AB The present invention provides a film-forming foamable cosmetic or pharmaceutical vehicle, and cosmetic and/or pharmaceutical compns. thereof. Specifically, the foamable composition, includes (1) about 6% to about 70% by weight of at least one organic carrier; (2) about 0.1% to about 5% by weight of at least one surface-active agent; (3) about 0.01% to about 5% by weight of at least one film forming agent; (4) water; and (5) about 3% to about 25% by weight of the total composition of at least one liquefied or compressed gas propellant. The composition is substantially alc. free and is used in treating, alleviating or preventing a disorder.

AN 2006:890398 HCAPLUS <<LOGINID::20080201>>
DN 145:298800

TI Film forming foamable pharmaceutical and cosmetic compositions and

cosmetic and therapeutic uses thereof
IN Tamarkin, Dov; Friedman, Doron; Eini, Meir
PA Foamix Ltd., Israel
SO U.S. Pat. Appl. Publ., 20pp., Cont.-in-part of U.S. Ser. No. 922,358.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 21

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006193789	A1	20060831	US 2006-337747	20060123 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005069566	A1	20050331	US 2004-911367	20040804 <--
	US 2005074414	A1	20050407	US 2004-922358	20040820 <--
	ZA 2005003298	A	20060830	ZA 2005-3298	20050425 <--
	AU 2006201878	A1	20070927	AU 2006-201878	20060504 <--
PRAI	IL 2002-152486	A	20021025 <--		
	US 2002-429546P	P	20021129 <--		
	US 2003-492385P	P	20030804 <--		
	US 2003-497648P	P	20030825 <--		
	WO 2003-IB5527	A2	20031024 <--		
	US 2004-911367	A2	20040804		
	US 2004-922358	A2	20040820		

L11 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Acidic drug complexes for improved bioavailability and delivery
AB Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition The compns. include a mol. complex formed between an acidic pharmaceutical drug and at least one functional substance. The compns. provide improved bioavailability and improved delivery of the drug into the cutaneous tissues. For example, methotrexate complex with L-lysine was found to have less skin irritation when applying topically to treat psoriasis on the forearm.
AN 2004:799452 HCAPLUS <<LOGINID::20080201>>
DN 141:301435
TI Acidic drug complexes for improved bioavailability and delivery
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004082628	A2	20040930	WO 2004-US8112	20040317 <--
	WO 2004082628	A3	20041119		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004220264	A1	20041104	US 2004-801134	20040316	<--
AU 2004222305	A1	20040930	AU 2004-222305	20040317	<--
CA 2519126	A1	20040930	CA 2004-2519126	20040317	<--
EP 1603549	A2	20051214	EP 2004-757550	20040317	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-454631P	P	20030317	<--	
US 2004-801134	A	20040316		
WO 2004-US8112	A	20040317		

OS MARPAT 141:301435

L11 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
TI N-Acetyl cysteine and its topical use
AB Methods to alleviate or improve various cosmetic conditions and dermatol. disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors using compns. comprising N-acetyl-cysteine (isomeric or non-isomeric forms) and/or free acid, salt, lactone, amide or ester forms of N-acetyl-cysteine are described. The methods provided may also comprise application of a composition further containing various cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.
AN 2003:971738 HCAPLUS <<LOGINID::20080201>>
DN 140:23273
TI N-Acetyl cysteine and its topical use
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Pat. Appl. 2003 198,656.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI US 2003229141	A1	20031211	US 2003-462885	20030617	<--
US 6159485	A	20001212	US 1999-227213	19990108	<--
EP 1570840	A2	20050907	EP 2004-29094	20000107	<--
EP 1570840	A3	20051116			

R: DE, ES, FR, GB, IT

EP 1639994	A2	20060329	EP 2005-18302	20000107	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

US 6524593	B1	20030225	US 2000-560901	20000428	<--
US 2003198656	A1	20031023	US 2003-371504	20030221	<--
US 6808716	B2	20041026			
PRAI US 1999-227213	A1	19990108	<--		
US 2000-560901	A2	20000428	<--		
US 2003-371504	A2	20030221	<--		
EP 2000-902347	A3	20000107	<--		

L11 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Urea compositions for the treatment of skin disorders
AB The invention is directed to compns., methods of making the compns., and methods of treating cosmetic and dermatol. disorders with a composition that includes a mol. complex between urea and a functional substance that has at least one hydroxyl group and one carboxyl group either as a free acid, a salt, an amide or a lactone. The compns. are stable when compared to

conventional urea-containing compns., and provide controlled-release of the urea. For example, urea 15 g was dissolved in 27 mL water and galacturonic acid 8 g was slowly added to form a mol. complex until the solution changed pH from 7.4 to 1.9. A clear solution containing the mol. complex was mixed with a hydrophilic ointment.

AN 2003:836770 HCAPLUS <<LOGINID::20080201>>
DN 139:341739
TI Urea compositions for the treatment of skin disorders
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003086291	A2	20031023	WO 2003-US10823	20030409 <--
WO 2003086291	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481702	A1	20031023	CA 2003-2481702	20030409 <--
AU 2003220691	A1	20031027	AU 2003-220691	20030409 <--
US 2004033963	A1	20040219	US 2003-409684	20030409 <--
EP 1492486	A2	20050105	EP 2003-717012	20030409 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2002-371157P	P	20020410 <--		
WO 2003-US10823	W	20030409 <--		

L11 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use
AB Compns. comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatol. disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compns. comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects. A cream was prepared by mixing 50 g of 50% maltobionic acid with 50 g oil-in-water base, pH = 1.7. Efficacy of topical maltobionic acid in treatment of dry skin is reported.
AN 2001:31287 HCAPLUS <<LOGINID::20080201>>
DN 134:105670
TI Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English

```
FAN.CNT 1
     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ---------------       ----   --------    --------------------     --------
PI   WO 2001001932          A2    20010111    WO 2000-US16301          20000628 <--
     WO 2001001932          A3    20010517
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6335023             B1    20020101    US 2000-487228           20000119 <--
     CA 2373852             A1    20010111    CA 2000-2373852          20000628 <--
     BR 2000011640          A     20020514    BR 2000-11640            20000628 <--
     EP 1227820             A2    20020807    EP 2000-950220           20000628 <--
     EP 1227820             B1    20060419
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     JP 2003503436          T     20030128    JP 2001-507430           20000628 <--
     AU 775620              B2    20040805    AU 2000-63353            20000628 <--
     CN 1635864             A     20050706    CN 2000-809776           20000628 <--
     AT 323498              T     20060515    AT 2000-950220           20000628 <--
     EP 1685843             A1    20060802    EP 2006-6895             20000628 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY
     PT 1227820             T     20060831    PT 2000-950220           20000628 <--
     ES 2262529             T3    20061201    ES 2000-950220           20000628 <--
     US 2002028227          A1    20020307    US 2001-987023           20011113 <--
     US 6740327             B2    20040525
     MX 2001PA13042         A     20030820    MX 2001-PA13042          20011217 <--
     HK 1048764             A1    20060915    HK 2003-100874           20030206 <--
     US 2004180854          A1    20040916    US 2004-811998           20040330 <--
     AU 2004212601          A1    20041014    AU 2004-212601           20040920 <--
     AU 2004212601          B2    20070614
     JP 2005232180          A     20050902    JP 2005-74658            20050316 <--
PRAI US 1999-141264P        P     19990630  <--
     US 2000-487228         A     20000119  <--
     AU 2000-63353          A     20000628  <--
     EP 2000-950220         A3    20000628  <--
     JP 2001-507430         A3    20000628  <--
     WO 2000-US16301        W     20000628  <--
     US 2001-987023         A1    20011113  <--
OS   MARPAT 134:105670


=> file registry
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                        ENTRY     SESSION
FULL ESTIMATED COST                                      0.12      387.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                        ENTRY     SESSION
CA SUBSCRIBER PRICE                                      0.00       -4.00

FILE 'REGISTRY' ENTERED AT 16:10:56 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.
```

STRUCTURE FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6
DICTIONARY FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10627994claim33.str





chain nodes :
14 15 17 18 20 21 28 29 34 36 44 45 46 47 48 49 50
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 22 23 24 25 26 27 37 38 39 40
41 42
chain bonds :
1-20 2-18 3-17 6-21 9-14 11-15 12-34 15-36 22-47 23-48 24-49 25-50 26-28
27-46 36-37 37-45 40-44
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13
22-23 22-27 23-24 24-25 25-26 26-27 37-38 37-42 38-39 39-40 40-41 41-42
exact/norm bonds :
7-11 8-13 9-14 11-12 12-13 37-38 37-42 38-39 39-40 40-41 40-44 41-42

exact bonds :
1-20 2-18 3-17 6-21 11-15 12-34 15-36 22-47 23-48 24-49 25-50 26-28
27-46

```
36-37  37-45
normalized bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  9-10  22-23  22-27  23-24  24-25
25-26  26-27


G1:H,n-Bu,C(O)CH3,[*1]

G2:H,Ph,PhO,NH2,Cl

Connectivity :
29:0 E exact RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  17:CLASS  18:CLASS  20:CLASS
21:CLASS  22:Atom  23:Atom
24:Atom  25:Atom  26:Atom  27:Atom  28:CLASS  29:CLASS  34:CLASS  36:CLASS  37:Atom
 38:Atom
39:Atom  40:Atom  41:Atom  42:Atom  44:CLASS  45:CLASS  46:CLASS  47:CLASS
48:CLASS  49:CLASS  50:CLASS

Generic attributes :
29:
Saturation              : Saturated

Element Count :
Node 15: Limited
    C,C1-10

Node 29: Limited
    C,C1-10




L12     STRUCTURE UPLOADED

=> s l12
SAMPLE SEARCH INITIATED 16:11:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       120 TO ITERATE

100.0% PROCESSED      120 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          1743 TO     3057
PROJECTED ANSWERS:                0 TO        0

L13           0 SEA SSS SAM L12

=> d l12
L12 HAS NO ANSWERS
L12             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l12 sss full
FULL SEARCH INITIATED 16:11:31 FILE 'REGISTRY'
```

FULL SCREEN SEARCH COMPLETED - 2193 TO ITERATE

100.0% PROCESSED 2193 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L14 0 SEA SSS FUL L12

=>
Uploading C:\Program Files\Stnexp\Queries\10627994claim34.str



chain nodes :
14 15 16 18 19 20 21 27 28 29 36 40 42 43 44 45 46 47
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 22 23 24 25 26 30 31 32 33 34
35
chain bonds :

```
1-18  2-16  3-15  6-19  9-14  11-21  12-20  14-40  14-42  27-28  27-29  27-30  28-36
31-43  32-44  33-45  34-46  35-47
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  7-11  8-9  8-13  9-10  11-12  12-13
22-23  22-26  23-24  24-25  25-26  30-31  30-35  31-32  32-33  33-34  34-35
exact/norm bonds :
7-11  8-13  9-14  11-12  12-13  12-20  14-42  22-23  22-26  23-24  24-25  25-26

exact bonds :
1-18  2-16  3-15  6-19  11-21  14-40  27-28  27-29  27-30  28-36  31-43  32-44
33-45
34-46  35-47
normalized bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  9-10  30-31  30-35  31-32  32-33
33-34  34-35


G1:H,Ph,[*1]

G2:H,Ph,[*1],[*2]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  18:CLASS  19:CLASS
20:CLASS  21:CLASS  22:Atom
23:Atom  24:Atom  25:Atom  26:Atom  27:CLASS  28:CLASS  29:CLASS  30:Atom  31:Atom
32:Atom
33:Atom  34:Atom  35:Atom  36:CLASS  40:CLASS  42:CLASS  43:CLASS  44:CLASS
45:CLASS  46:CLASS  47:CLASS



L15     STRUCTURE UPLOADED

=> d l15
L15 HAS NO ANSWERS
L15             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l15
SAMPLE SEARCH INITIATED 16:12:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      554 TO ITERATE

100.0% PROCESSED      554 ITERATIONS                                  1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          9668 TO    12492
PROJECTED ANSWERS:                1 TO       80

L16           1 SEA SSS SAM L15

=> d l16 scan

L16  1 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   3H-Imidazo[4,5-c]quinolin-4-amine
MF   C10 H8 N4
```

CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l15 sss full
FULL SEARCH INITIATED 16:12:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11522 TO ITERATE

100.0% PROCESSED 11522 ITERATIONS 30 ANSWERS
SEARCH TIME: 00.00.01

L17 30 SEA SSS FUL L15

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	356.72	744.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.00

FILE 'CAPLUS' ENTERED AT 16:12:18 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Feb 2008 VOL 148 ISS 6
FILE LAST UPDATED: 31 Jan 2008 (20080131/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l17
L18 45 L17

```
=> s l17/thu
            45 L17
        974326 THU/RL
L19          19 L17/THU
                (L17 (L) THU/RL)

=> file stnguide
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.60     746.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.00

FILE 'STNGUIDE' ENTERED AT 16:12:33 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.06     746.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.00

FILE 'HCAPLUS' ENTERED AT 16:13:16 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 1 Feb 2008  VOL 148 ISS 6
FILE LAST UPDATED: 31 Jan 2008  (20080131/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l9 and l18

            45 L17
L20          0 L9 AND L18

=> s l20 and (PY<2004 or AY<2004 or PRY<2004)

      23975504 PY<2004
       4760001 AY<2004
```

```
       4238501 PRY<2004
L21          0 L20 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.69     749.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.00

FILE 'STNGUIDE' ENTERED AT 16:13:21 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 25, 2008 (20080125/UP).

<------User Break------>

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.06     749.72

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.00

FILE 'HCAPLUS' ENTERED AT 16:13:43 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 1 Feb 2008  VOL 148 ISS 6
FILE LAST UPDATED: 31 Jan 2008  (20080131/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l19 and cosmetic
COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> s l18 and cosmetic
           45 L17
        63301 COSMETIC
```

```
L22           0 L18 AND COSMETIC

=> s l18 and topical
            45 L17
         48666 TOPICAL
L23           8 L18 AND TOPICAL

=> d l23 1-8 ti abs bib

L23  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Recombinant viral vaccine
AB   The present invention concerns new recombinant viral vaccines.  In
     particular the present invention provides combination products that
     comprise recombinant viral vectors and specific compds. able to improve
     the immune response raised in vivo by said recombinant viral vectors.  The
     invention describes the use of a viral vector, such as a poxvirus,
     encoding an antigen in combination with a 1H-imidazo[4,5-c]quinolin-4-
     amine derivative cream, such as imiquimod (Aldara), as an immune response
     modifier for use in vaccines.  The combination was shown to induce Th1
     responses to the antigen of interest.
AN   2007:1469232  HCAPLUS <<LOGINID::20080201>>
DN   148:99087
TI   Recombinant viral vaccine
IN   Bonnefoy, Jean-Yves; Paul, Stephane
PA   Transgene S.A., Fr.
SO   PCT Int. Appl., 87pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2007147529         A2    20071227    WO 2007-EP5303          20070615
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG,
             MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
             RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
             TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
PRAI EP 2006-360028        A     20060620
     US 2006-852964P       P     20061020

L23  ANSWER 2 OF 8  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Imidazoquinoline adjuvants for vaccines
AB   The author discloses that topical administration of
     imidazoquinolines (e.g., imiquimod) enhances the T-cell response to
     genetic immunization.  In one example, the interferon-γ-producing
     CD8+ T-cell response to HBsAg was enhanced by the topical
     administration of Aldara.
AN   2006:388764  HCAPLUS <<LOGINID::20080201>>
DN   144:410797
TI   Imidazoquinoline adjuvants for vaccines
IN   Braun, Ralph Patrick
PA   Powdermed Limited, USA
SO   U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 102,615.
     CODEN: USXXCO
DT   Patent
LA   English
```

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006088542	A1	20060427	US 2004-508143	20041118
	US 2003185835	A1	20031002	US 2002-102615	20020319
	WO 2003080114	A2	20031002	WO 2003-GB1203	20030319
	WO 2003080114	A3	20031106		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	US 2002-102615	B2	20020319
	US 2002-366057P	P	20020319
	WO 2003-GB1203	W	20030319

OS MARPAT 144:410797

L23 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Adjuvant compositions and particle-delivered codon-optimized DNA vaccines encoding HIV antigens, useful in prophylaxis and treatment of HIV infections

AB The present invention relates to certain adjuvant compns., and to vaccine and/or nucleic acid immunization strategies employing such compns. The invention in particular relates to DNA vaccines that are useful in the prophylaxis and treatment of HIV infections, more particularly when administered by particle mediated delivery. The examples disclose the use of imiquimod, in the form of Aldara cream, to enhance immune response to DNA vaccines encoding viral antigens, epitopes and fusions thereof. Also disclosed is the optimization of the viral coding sequences to more closely resemble the codon usage of highly expressed human genes. Methods used include gold particle-mediated immunization of plasmid DNA using "gene gun" DNA cartridges.

AN 2005:1261796 HCAPLUS <<LOGINID::20080201>>

DN 144:21828

TI Adjuvant compositions and particle-delivered codon-optimized DNA vaccines encoding HIV antigens, useful in prophylaxis and treatment of HIV infections

IN Braun, Ralph Patrick; Thomsen, Lindy; Van-Wely, Catherine; Ertl, Peter

PA Powdermed Limited, UK; Glaxo Group Limited

SO U.S. Pat. Appl. Publ., 75 pp., Cont.-in-part of U.S. Ser. No. 102,622.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005266024	A1	20051201	US 2005-507928	20050509
	US 2003190308	A1	20031009	US 2002-102622	20020319
	WO 2003080112	A2	20031002	WO 2003-GB1213	20030319
	WO 2003080112	A3	20031106		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2005256070 A1 20051117 US 2005-29465 20050106
PRAI US 2002-102622 A2 20020319
US 2002-366058P P 20020319
WO 2003-GB1213 W 20030319
OS MARPAT 144:21828

L23 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production
AB 1H-Imidazo-[4,5-c]quinolines were prepared while investigating novel nucleoside analogs as potential antiviral agents. While these compds. showed no direct antiviral activity when tested in a number of cell culture systems, some demonstrated potent inhibition of virus lesion development in an intravaginal guinea pig herpes simplex virus-2 assay. It was determined that the in vivo antiviral activity can be attributed to the ability of these mols. to induce the production of cytokines, especially interferon (IFN), in this model. Subsequently, it was found that the compds. also induce in vitro production of IFN in human peripheral blood mononuclear cells (hPBMCs). The in vitro results reported herein and the in vivo results reported previously led to the discovery of imiquimod which was developed as a topical agent and has been approved for the treatment of genital warts, actinic keratosis, and superficial basal cell carcinoma.
AN 2005:345257 HCAPLUS <<LOGINID::20080201>>
DN 143:43830
TI Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production
AU Gerster, John F.; Lindstrom, Kyle J.; Miller, Richard L.; Tomai, Mark A.; Birmachu, Woubalem; Bomersine, Shannon N.; Gibson, Shiela J.; Imbertson, Linda M.; Jacobson, Joel R.; Knafla, Roy T.; Maye, Peter V.; Nikolaides, Nickolas; Oneyemi, Folakemi Y.; Parkhurst, Gwen J.; Pecore, Sharon E.; Reiter, Michael J.; Scribner, Lisa S.; Testerman, Tracy L.; Thompson, Natalie J.; Wagner, Tammy L.; Weeks, Charles E.; Andre, Jean-Denis; Lagain, Daniel; Bastard, Yvon; Lupu, Michel
CS 3M Center, 3M Pharmaceuticals, St. Paul, MN, 55144-1000, USA
SO Journal of Medicinal Chemistry (2005), 48(10), 3481-3491
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 143:43830
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Immunostimulatory combinations and treatments
AB The present invention provides immunostimulatory combinations and methods. Generally, the immunostimulatory combinations include a topical formulation of an immuno response modifier (IRM) compound and a pharmaceutical composition Generally, the methods include administering (a) a topical formulation of an IRM compound, and (b) a pharmaceutical composition to an administration site of a subject. A topical cream contained 2-propylthiazolo[4,5-c]quinolin-4-amine 1.00, isostearic acid 5.00, iso-Pr myristate 10.00, Poloxamer-188, 2.50, edetate disodium 0.05, Carbomer-974 1.50, propylene glycol 15.00, propylparaben 0.10, methylparaben 0.20, purified water 63.95, and 20% NaOH 0.70%.
AN 2005:177852 HCAPLUS <<LOGINID::20080201>>
DN 142:266767
TI Immunostimulatory combinations and treatments
IN Kedl, Ross M.; Tomai, Mark A.; Vasilakos, John P.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005018574	A2	20050303	WO 2004-US27712	20040825
	WO 2005018574	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004266162	A1	20050303	AU 2004-266162	20040825
	CA 2551075	A1	20050303	CA 2004-2551075	20040825
	AU 2004268616	A1	20050310	AU 2004-268616	20040825
	CA 2536249	A1	20050310	CA 2004-2536249	20040825
	WO 2005020912	A2	20050310	WO 2004-US27633	20040825
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1658035	A2	20060524	EP 2004-782185	20040825
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	EP 1660122	A2	20060531	EP 2004-801917	20040825
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007503268	T	20070222	JP 2006-524827	20040825
	JP 2007504145	T	20070301	JP 2006-524843	20040825
PRAI	US 2003-497628P	P	20030825		
	US 2003-524213P	P	20031121		
	WO 2004-US27633	W	20040825		
	WO 2004-US27712	W	20040825		

L23 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Immune adjuvant comprising imidazoquinoline amine or imidazopyridine amine for nucleic acid vaccine delivery

AB The invention relates to the fields of vaccines, vaccine adjuvants, mol. biol. and immunol., and generally relates to adjuvants and nucleic acid immunization techniques. More specifically, the invention relates to certain adjuvant compns., and to vaccine and/or nucleic acid immunization strategies employing such compns. The adjuvant compound is an imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- or oxazolo-quinolinamine or pyridinamines, imidazonaphthyridine or tetrahydroimidazonaphthyridine amine; especially imidazoquinoline, imiquimod or resiquimod. The vaccine is DNA vaccine comprising gene encoding HBsAg, HSV-2 antigen (e.g. gD or gB protein), cholera toxin or HSP70. The vaccine compns. are administered topically or transdermally in the forms of particles or creams.

AN 2003:777630 HCAPLUS <<LOGINID::20080201>>

DN 139:291106
TI Immune adjuvant comprising imidazoquinoline amine or imidazopyridine amine for nucleic acid vaccine delivery
IN Braun, Ralph Patrick
PA Powderject Research Limited, UK
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080114	A2	20031002	WO 2003-GB1203	20030319
	WO 2003080114	A3	20031106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003185835	A1	20031002	US 2002-102615	20020319
	CA 2484049	A1	20031002	CA 2003-2484049	20030319
	AU 2003216851	A1	20031008	AU 2003-216851	20030319
	EP 1487485	A2	20041222	EP 2003-712390	20030319
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005526793	T	20050908	JP 2003-577939	20030319
	US 2006088542	A1	20060427	US 2004-508143	20041118
PRAI	US 2002-102615	A	20020319		
	US 2002-366057P	P	20020319		
	WO 2003-GB1203	W	20030319		

OS MARPAT 139:291106

L23 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Immune adjuvant comprising imidazoquinoline or imidazopyridine amines for DNA vaccines
AB The invention relates to certain adjuvant compns., and to vaccine and/or nucleic acid immunization strategies employing such compns. The invention in particular relates to DNA vaccines that are useful in the prophylaxis and treatment of HIV infections, more particularly when administered by particle mediated delivery. The adjuvant uses imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- and oxazoloquinolinamine or pyridinamine, imidazonaphthyridine or tetrahydronaphthyridine amine to enhance immune response.
AN 2003:777628 HCAPLUS <<LOGINID::20080201>>
DN 139:291105
TI Immune adjuvant comprising imidazoquinoline or imidazopyridine amines for DNA vaccines
IN Braun, Ralph Patrick; Thomsen, Lindy; Van-Wely, Catherine; Ertl, Peter
PA Powderject Research Limited, UK; Glaxo Group Limited
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080112	A2	20031002	WO 2003-GB1213	20030319
	WO 2003080112	A3	20031106		

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
            TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    US 2003190308        A1    20031009    US 2002-102622        20020319
    CA 2484044           A1    20031002    CA 2003-2484044       20030319
    AU 2003216852        A1    20031008    AU 2003-216852        20030319
    EP 1487486           A2    20041222    EP 2003-712391        20030319
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    JP 2005533752        T     20051110    JP 2003-577938        20030319
    US 2005256070        A1    20051117    US 2005-29465         20050106
    US 2005266024        A1    20051201    US 2005-507928        20050509
PRAI US 2002-102622      A     20020319
    US 2002-366058P      P     20020319
    WO 2003-GB1213       W     20030319
OS  MARPAT 139:291105

L23 ANSWER 8 OF 8  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI  Use of imidazoquinolinamines as adjuvants in DNA vaccination
AB  The present invention relates to the use of a 1H-imidazo[4,5-c]quinolin-4-
    amine derivative as an adjuvant for use with nucleic acid vaccination.  The
    vaccine comprises the adjuvant and a nucleotide sequence encoding an
    antigen associated with a disease.  The diseases can include infection,
    cancer, allergy, and autoimmunity.
AN  2002:240588  HCAPLUS <<LOGINID::20080201>>
DN  136:261816
TI  Use of imidazoquinolinamines as adjuvants in DNA vaccination
IN  Thomsen, Lindy Louise; Tite, John Philip; Topley, Peter
PA  Glaxo Group Limited, UK
SO  PCT Int. Appl., 62 pp.
    CODEN: PIXXD2
DT  Patent
LA  English
FAN.CNT 2
    PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
    ---------------      ----   --------    --------------------    --------
PI  WO 2002024225        A1     20020328    WO 2001-GB4207          20010920
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
            PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
            US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2422863           A1     20020328    CA 2001-2422863         20010920
    AU 2001087908        A      20020402    AU 2001-87908           20010920
    EP 1318835           A1     20030618    EP 2001-967535          20010920
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    BR 2001013982        A      20030819    BR 2001-13982           20010920
    HU 2003001180        A2     20040301    HU 2003-1180            20010920
    JP 2004509150        T      20040325    JP 2002-528295          20010920
    NZ 524792            A      20040924    NZ 2001-524792          20010920
    CA 2461056           A1     20030327    CA 2002-2461056         20020918
    WO 2003025003        A2     20030327    WO 2002-EP10592         20020918
```

```
     WO 2003025003          A3     20031204
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002362368          A1     20030401    AU 2002-362368          20020918
     EP 1427826             A2     20040616    EP 2002-798748          20020918
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     BR 2002012619          A      20040817    BR 2002-12619           20020918
     HU 2004002259          A2     20050128    HU 2004-2259            20020918
     CN 1606624             A      20050413    CN 2002-823087          20020918
     JP 2005511019          T      20050428    JP 2003-528849          20020918
     NZ 531814              A      20051028    NZ 2002-531814          20020918
     NO 2003001274          A      20030519    NO 2003-1274            20030319
     MX 2003PA02453         A      20030619    MX 2003-PA2453          20030319
     ZA 2003002231          A      20040505    ZA 2003-2231            20030320
     IN 2003DN00419         A      20070302    IN 2003-DN419           20030320
     US 2004076633          A1     20040422    US 2003-380981          20030923
     ZA 2004002189          A      20050429    ZA 2004-2189            20040318
     NO 2004001157          A      20040519    NO 2004-1157            20040319
     MX 2004PA02631         A      20040708    MX 2004-PA2631          20040319
     IN 2004KN00369         A      20060217    IN 2004-KN369           20040319
     US 2007015721          A1     20070118    US 2004-490011          20041025
     US 2007248614          A1     20071025    US 2007-764814          20070619
PRAI GB 2000-23008          A      20000920
     WO 2001-GB4207         W      20010920
     GB 2001-29604          A      20011211
     GB 2002-6462           A      20020319
     WO 2002-EP10592        W      20020918
     US 2003-380981         A1     20030923
OS   MARPAT 136:261816
RE.CNT  3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   25.97     775.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -6.40     -10.40

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:14:12 ON 01 FEB 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
```

```
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 16:14:31 ON 01 FEB 2008
FILE 'HCAPLUS' ENTERED AT 16:14:31 ON 01 FEB 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      25.97     775.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -6.40     -10.40

=> d hisd
'HISD' IS NOT A VALID FORMAT FOR FILE 'HCAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
```

```
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):d his
'D' IS NOT A VALID FORMAT FOR FILE 'HCAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs
```

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):ti

L23 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Recombinant viral vaccine

=> d his

(FILE 'HOME' ENTERED AT 16:01:43 ON 01 FEB 2008)

FILE 'REGISTRY' ENTERED AT 16:02:11 ON 01 FEB 2008
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 2 S L1 SSS FULL
L4 1 S IMIQUIMOD/CN
L5 STRUCTURE UPLOADED
L6 4 S L5
L7 37 S L5 SSS FULL

FILE 'STNGUIDE' ENTERED AT 16:07:44 ON 01 FEB 2008

FILE 'HCAPLUS' ENTERED AT 16:09:29 ON 01 FEB 2008
L8 539 S L7
L9 8923 S (FINE LINE) OR WRINKLE
L10 8 S L8 AND L9
L11 5 S L10 AND (PY<2004 OR AY<2004 OR PRY<2004)

FILE 'STNGUIDE' ENTERED AT 16:09:35 ON 01 FEB 2008

FILE 'HCAPLUS' ENTERED AT 16:09:42 ON 01 FEB 2008

FILE 'STNGUIDE' ENTERED AT 16:09:43 ON 01 FEB 2008

FILE 'REGISTRY' ENTERED AT 16:10:56 ON 01 FEB 2008
L12 STRUCTURE UPLOADED
L13 0 S L12
L14 0 S L12 SSS FULL
L15 STRUCTURE UPLOADED
L16 1 S L15
L17 30 S L15 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:12:18 ON 01 FEB 2008
L18 45 S L17
L19 19 S L17/THU

FILE 'STNGUIDE' ENTERED AT 16:12:33 ON 01 FEB 2008

FILE 'HCAPLUS' ENTERED AT 16:13:16 ON 01 FEB 2008
L20 0 S L9 AND L18
L21 0 S L20 AND (PY<2004 OR AY<2004 OR PRY<2004)

FILE 'STNGUIDE' ENTERED AT 16:13:21 ON 01 FEB 2008

```
     FILE 'HCAPLUS' ENTERED AT 16:13:43 ON 01 FEB 2008
L22            0 S L18 AND COSMETIC
L23            8 S L18 AND TOPICAL

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      29.02     778.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -6.40     -10.40

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:14:50 ON 01 FEB 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 16:32:31 ON 01 FEB 2008
FILE 'HCAPLUS' ENTERED AT 16:32:31 ON 01 FEB 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      29.02     778.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -6.40     -10.40

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      29.02     778.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -6.40     -10.40

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 16:32:46 ON 01 FEB 2008

69 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s imiquimod and ((fine lines) or wrinkle or wrinkles)
          1   FILE ADISINSIGHT
         11   FILE CAPLUS
          3   FILE EMBASE
         22   FILE IFIPAT
```

```
  37 FILES SEARCHED...
           3   FILE PROMT
           1   FILE TOXCENTER
          81   FILE USPATFULL
           3   FILE USPAT2
  63 FILES SEARCHED...
          12   FILE WPIDS
          12   FILE WPINDEX

  10 FILES HAVE ONE OR MORE ANSWERS,   69 FILES SEARCHED IN STNINDEX

L24  QUE IMIQUIMOD AND ((FINE LINES) OR WRINKLE OR WRINKLES)

=> fine embase
FINE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s imiquimod and cosmetic
           6   FILE ADISCTI
           1   FILE ADISINSIGHT
           1   FILE ADISNEWS
           9   FILE BIOSIS
           2   FILE BIOTECHNO
           2   FILE CABA
          21   FILE CAPLUS
           8   FILE DDFU
          12   FILE DRUGU
           1   FILE EMBAL
          80   FILE EMBASE
          17   FILE ESBIOBASE
          23   FILE IFIPAT
           4   FILE KOSMET
           1   FILE LIFESCI
          36   FILE MEDLINE
  46 FILES SEARCHED...
          25   FILE PASCAL
           1   FILE PHIN
          32   FILE PROMT
          32   FILE SCISEARCH
          21   FILE TOXCENTER
         232   FILE USPATFULL
          30   FILE USPAT2
          10   FILE WPIDS
          10   FILE WPINDEX

  25 FILES HAVE ONE OR MORE ANSWERS,   69 FILES SEARCHED IN STNINDEX

L25  QUE IMIQUIMOD AND COSMETIC

=> file embase
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY     SESSION
FULL ESTIMATED COST                               1.95      780.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY     SESSION
CA SUBSCRIBER PRICE                               0.00      -10.40

FILE 'EMBASE' ENTERED AT 16:34:49 ON 01 FEB 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

 FILE COVERS 1974 TO 1 Feb 2008 (20080201/ED)
```

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

```
=> s imiquimod and ((fine lines) or wrinkle or wrinkles)
          2095 IMIQUIMOD
         55758 "FINE"
        174930 "LINES"
            67 FINE LINES
                 ("FINE"(W)"LINES")
          1208 WRINKLE
          1114 WRINKLES
L26          3 IMIQUIMOD AND ((FINE LINES) OR WRINKLE OR WRINKLES)

=> d l26 1-3 ti abs bib

L26  ANSWER 1 OF 3  EMBASE  COPYRIGHT (c) 2008 Elsevier B.V. All rights
     reserved on STN
TI   Imiquimod 5% cream reverses histologic changes and improves
     appearance of photoaged facial skin.
AB   Ten healthy women with moderate signs of facial photodamage (fine
     lines, wrinkles, dyspigmentations, hyperkeratotic
     prominent pores, and poor skin texture) applied imiquimod 5%
     cream once daily for 5 days each week for 4 weeks.  None of the subjects
     had actinic keratoses or had received previous treatment for basal or
     squamous cell cancers.  Histology, hydration, coloration, and imaging
     assessments were conducted before and after treatment to determine the
     effects of imiquimod therapy.  Global assessments of the
     improvement in skin appearance were evaluated by subjects and a
     dermatologist.  Histologic analysis revealed that the structurally
     regressive changes of the epidermis - atrophy, atypia, hyperchromatic
     nuclei, disorderly differentiation, and loss of polarity - were completely
     reversed after imiquimod treatment.  The dermal matrix was
     unaffected by imiquimod therapy.  Global assessments of skin
     appearance revealed that imiquimod treatment yielded appreciable
     reductions in wrinkles, dyspigmentations, and hyperkeratotic
     pores.  Clinical improvements in skin appearance were confirmed by
     imaging, coloration, and hydration assessments that demonstrated a
     smoother surface, more uniform color, improved texture, and elimination of
     hyperkeratotic pores.  The correction of epidermal dysplasia, a
     characteristic feature of photoaged skin in which epithelial tumors arise,
     suggests that imiquimod exerts a prophylactic action in the
     prevention of cutaneous tumors.  Imiquimod provides an
     alternative to topical retinoids in reversing the clinical and
     histologically regressive changes of photoaged facial skin.
AN   2007086734  EMBASE   <<LOGINID::20080201>>
TI   Imiquimod 5% cream reverses histologic changes and improves
     appearance of photoaged facial skin.
AU   Kligman A.M.; Zhen Y.; Sadiq I.; Stoudemayer T.
CS   Dr. A.M. Kligman, S.K.I.N., Inc., Conshohocken, PA, United States
SO   Cosmetic Dermatology, (Nov 2006) Vol. 19, No. 11, pp. 704-711.
     Refs: 18
     ISSN: 1041-3766  CODEN: CDOEBQ
CY   United States
```

DT Journal; Article
FS 013 Dermatology and Venereology
037 Drug Literature Index
038 Adverse Reactions Titles
005 General Pathology and Pathological Anatomy
LA English
SL English
ED Entered STN: 22 Mar 2007
Last Updated on STN: 22 Mar 2007

L26 ANSWER 2 OF 3 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI NewFill for skin augmentation: A new filler or failure?.
AB BACKGROUND. New injectable materials for skin augmentation that promise to be the ideal filling material are introduced every year. Recently, we treated three patients with adverse reactions to a new substance for skin augmentation: polylactic acid (NewFill, Ashford Aesthetics Inc, Belgium). OBJECTIVE. To present three cases in which serious adverse reactions had occurred after skin augmentation with a new filling substance, polylactic acid (NewFill). Because an identical substance (Sculptra, Aventis Pharmaceuticals, Bridgewater, NJ, USA) was recently introduced in the United States, we want to alert future users of these substances to possible adverse events. MATERIALS AND METHODS. We report three cases with serious adverse events more than 12 months after skin augmentation with polylactic acid (NewFill). They were treated with intralesional steroid therapy and topical imiquimod application. RESULTS. Both intralesional steroid therapy and topical imiquimod application lead to moderate results. If feasible, surgical excision is the best available option. CONCLUSIONS. Great care should be taken when polylactic acid is used for intradermal injection because giant cell granulomatous reactions may be the result. Other than surgical excision, effective treatment options are lacking. .COPYRGT. 2005 by the American Society for Dermatologic Surgery, Inc.
AN 2006037703 EMBASE <<LOGINID::20080201>>
TI NewFill for skin augmentation: A new filler or failure?.
AU Beljaards R.C.; De Roos K.-P.; Bruins F.G.
CS Dr. K.-P. De Roos, Department of Dermatology, Ziekenhuis, Bernhoven, PO Box 10.000, Veghel, Netherlands
SO Dermatologic Surgery, (2005) Vol. 31, No. 7 PART I, pp. 772-776.
Refs: 13
ISSN: 1076-0512 CODEN: DESUFE
CY United States
DT Journal; Article
FS 013 Dermatology and Venereology
027 Biophysics, Bioengineering and Medical Instrumentation
037 Drug Literature Index
LA English
SL English
ED Entered STN: 3 Mar 2006
Last Updated on STN: 3 Mar 2006

L26 ANSWER 3 OF 3 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Introduction to skin cancer.
AB The incidence of skin cancer has been increasing throughout the United States and much of the world. Although the mortality rate of nonmelanoma skin cancer (NMSC) is low, NMSC accounts for considerable morbidity, including cosmetic and functional impairment. Melanoma, although less common, is a life-threatening malignancy if not detected and treated early. Skin cancer also significantly contributes to the rising costs of health care in the United States. NMSC is estimated to be among the five most costly cancers to Medicare in the United States [1]. Prevention, early diagnosis, and treatment are critical in helping to reduce the incidence, morbidity, and mortality associated with skin cancer. This

article provides an introduction to skin cancer, including the changing incidence, clinical presentation, and summary of treatment and prognosis. .COPYRGT. 2005 Elsevier Inc. All rights reserved.
AN 2005194030 EMBASE <<LOGINID::20080201>>
TI Introduction to skin cancer.
AU Kenneaster D.G.
CS D.G. Kenneaster, Carle Clinic Association, 1813 West Kirby Avenue, Champaign, IL 61821, United States. Derek.Kenneaster@carle.com
SO Oral and Maxillofacial Surgery Clinics of North America, (May 2005) Vol. 17, No. 2 SPEC. ISS., pp. 133-142.
Refs: 82
ISSN: 1042-3699 CODEN: OMSCAU
PUI S 1042-3699(05)00008-7
CY United States
DT Journal; Article
FS 013 Dermatology and Venereology
016 Cancer
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
005 General Pathology and Pathological Anatomy
LA English
SL English
ED Entered STN: 12 May 2005
Last Updated on STN: 12 May 2005

=> s imiquimod and cosmetic
2095 IMIQUIMOD
20477 COSMETIC
L27 80 IMIQUIMOD AND COSMETIC

=> s l27 not (PY>2003)
2307210 PY>2003
L28 14 L27 NOT (PY>2003)

=> d l28 1-14 ti

L28 ANSWER 1 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Current treatment patterns in non-melanoma skin cancer across Europe.

L28 ANSWER 2 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Combined imiquimod and acitretin for non-surgical treatment of basal cell carcinoma.

L28 ANSWER 3 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod.

L28 ANSWER 4 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Lip silicone granulomatous foreign body reaction treated with Aldara (imiquimod 5%).

L28 ANSWER 5 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Topical 3% diclofenac in 2.5% hyaluronic acid gel: A review of its use in patients with actinic keratoses.

L28 ANSWER 6 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

TI Photodynamic therapy: Is it a valuable treatment option for actinic keratoses?.

L28 ANSWER 7 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI [Perspectives for dermatology in the 21st century]. DERMATOLOGISCHE PERSPEKTIVEN IM 21. JAHRHUNDERT.

L28 ANSWER 8 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI A case of squamous cell carcinoma in situ in renal transplant patient treated with 5% imiquimod.

L28 ANSWER 9 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI The role of the pharmaceutical industry in drug development in dermatology.

L28 ANSWER 10 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: A case report.

L28 ANSWER 11 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial.

L28 ANSWER 12 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Treatment of genital warts - What's the evidence?.

L28 ANSWER 13 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI [The bio-induction-therapy with imiquimod in solitary keratoacanthoma - A therapeutical alternative?]. DIE BIOINDUKTIONSTHERAPIE MIT IMIQUIMOD BEIM SOLITAREN KERATOAKANTHOM - EINE THERAPEUTISCHE ALTERNATIVE?.

L28 ANSWER 14 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI [Successful treatment of a superficial basal cell carcinoma with topical imiquimod]. ERFOLGREICHE TOPISCHE THERAPIE EINES OBERFLAACHLICHEN BASALIOMS MIT IMIQUIMOD.

=> d l28 2 3 4 5 7 9 ti abs bib

L28 ANSWER 2 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Combined imiquimod and acitretin for non-surgical treatment of basal cell carcinoma.
AB We report the successful outcome of treatment of a basal cell carcinoma (BCC) with topical imiquimod and systemic acitretin in a 48-year-old woman. We think that this treatment is a possible option for management of these non-life-threatening tumours. Experimental evidence suggests that combination treatment with retinoids increase the effects of imiquimod and would therefore seem to be possible when treating superficial tumours in areas where the cosmetic outcome is particularly important.
AN 2003445258 EMBASE <<LOGINID::20080201>>
TI Combined imiquimod and acitretin for non-surgical treatment of basal cell carcinoma.

AU Ingves C.; Jemec G.B.E.
CS Dr. C. Ingves, Department of Plastic Surgery, Roskilde Amtssygehus, DK 4000, Roskilde, Denmark
SO Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, (2003) Vol. 37, No. 5, pp. 293-295.
Refs: 22
ISSN: 0284-4311 CODEN: SJPSEM
CY Norway
DT Journal; Article
FS 013 Dermatology and Venereology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 20 Nov 2003
Last Updated on STN: 20 Nov 2003

L28 ANSWER 3 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod.
AB Background: Treatment of cutaneous leishmaniasis can be painful and protracted and cosmetic results are often unsatisfying. The immune modulator imiquimod has been reported to be suitable for the treatment of a variety of infectious skin diseases and neoplasias. Objective: We investigated the efficacy of topical application of imiquimod in the treatment of old world leishmaniasis in a placebo-controlled prospective study. Methods: Twelve patients were treated with imiquimod cream using a standard protocol, i.e. topical application three times a week, and a further three served as control group. Results: Lesions of cutaneous leishmaniasis regressed within the first 2-4 weeks in 10 of the 12 patients, whereas in two patients no change was observed. However, after 8 weeks all lesions showed progression. Conclusion: Our results thus demonstrate that topical application of imiquimod alone is ineffective in treating old world cutaneous leishmaniasis. Further studies are required to demonstrate a possible benefit of imiquimod in combination with other, preferably orally administered medicines.
AN 2003291158 EMBASE <<LOGINID::20080201>>
TI Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod.
AU Seeberger J.; Daoud S.; Pammer J.
CS Dr. J. Pammer, Institute of Clinical Pathology, University of Vienna, Allgemeines Krankenhaus Wien, Wahringer Gurtel 18-20, 1097 Vienna, Austria. Johannes.Pammer@akh-wien.ac.at
SO International Journal of Dermatology, (1 Jul 2003) Vol. 42, No. 7, pp. 576-579.
Refs: 16
ISSN: 0011-9059 CODEN: IJDEBB
CY United Kingdom
DT Journal; Conference Article; (Conference paper)
FS 013 Dermatology and Venereology
030 Clinical and Experimental Pharmacology
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 31 Jul 2003
Last Updated on STN: 31 Jul 2003

L28 ANSWER 4 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Lip silicone granulomatous foreign body reaction treated with Aldara (

imiquimod 5%).

AB We report a case of a lip granulomatous reaction after injection of silicone being treated successfully with topical Aldara (Imiquimod 5%). Silicone granulomas and the inflammatory foreign body reaction that can occur are some of the complications that arise from using silicone for cosmetic enhancement. The inflammatory reaction of this patient first appeared shortly after silicone injection of both the upper and lower lips. Histopathologic examination revealed a foreign body inflammatory reaction that is consistent with silicone granuloma. Although this reaction has been described extensively in the dermatologic literature as one of the disfiguring side effects of silicone injection, its treatment has plagued cosmetic dermatologists. We report the use of an immunomodulatory cream Aldara (Imiquimod 5%) to treat this type of reaction.

AN 2003152307 EMBASE <<LOGINID::20080201>>

TI Lip silicone granulomatous foreign body reaction treated with Aldara (imiquimod 5%).

AU Baumann L.S.; Halem M.L.

CS Dr. L.S. Baumann, 1295 Northwest 14th Street, Miami, FL 33125-1600, United States

SO Dermatologic Surgery, (1 Apr 2003) Vol. 29, No. 4, pp. 429-432.
Refs: 11
ISSN: 1076-0512 CODEN: DESUFE

CY United States

DT Journal; Article

FS 013 Dermatology and Venereology
027 Biophysics, Bioengineering and Medical Instrumentation
037 Drug Literature Index
009 Surgery

LA English

SL English

ED Entered STN: 1 May 2003
Last Updated on STN: 1 May 2003

L28 ANSWER 5 OF 14 EMBASE

TI Topical 3% diclofenac in 2.5% hyaluronic acid gel: A review of its use in patients with actinic keratoses.

AB Topical 3% diclofenac in 2.5% hyaluronic acid (HA) gel (diclofenac HA gel; Solaraze®(1)) is an NSAID approved for the treatment of actinic keratoses (AK). The efficacy of diclofenac HA gel (0.5g applied twice daily to each 5cm x 5cm treatment area) in patients with AK has been evaluated in three randomized, double-blind, HA gel vehicle-controlled trials. In each trial, efficacy was assessed 30 days after the end of treatment because an earlier study revealed that resolution of lesions was greater when measured after a 4 week interval, rather than at the end of treatment. In two fully published multicenter trials, there was no difference in baseline characteristics of the study groups. In a further single center study (not yet published), patients randomized to diclofenac HA gel had a significantly higher mean number of target lesions at baseline compared with HA gel vehicle. In the two published studies, the efficacy of diclofenac HA gel increased with increased treatment duration. When compared with HA gel vehicle recipients, significant improvements in total lesion number scores (TLNS), cumulative lesion number scores (CLNS), patient global improvement indices (PGII) and investigator global improvement indices (IGII) were obtained in patients treated for 60 and 90 but not 30 days with diclofenac HA gel. Fifty percent of patients treated for 90 days with diclofenac HA gel (vs 20% in HA gel vehicle recipients) and 33% of those treated for 60 days (vs 10%) had TLNS CLNS of zero at the end of follow-up. In the third trial, in which treatment was applied for 90 days, there was no statistically significant difference in the proportion of patients with TLNS or CLNS of zero at the end of follow-up. However, when controlling for the significant difference in mean baseline target lesion scores by calculating the mean change from baseline in

lesion counts, TLNS and CLNS were significantly lower in recipients of diclofenac HA gel than HA gel vehicle at the end of follow-up. Pruritus was the most frequently reported adverse event in all trials and the incidence was generally similar or lower in patients treated with diclofenac HA gel than HA gel vehicle. In conclusion, diclofenac HA gel produces significant reductions in the number of AK lesions, and can produce complete clearance of lesions when applied twice daily for 60 or 90 days. The product is well tolerated and did not produce serious adverse cosmetic effects in clinical trials. Thus, diclofenac HA gel represents a useful addition to the array of pharmacologic treatments available for AK.

AN 2003141503 EMBASE <<LOGINID::20080201>>
TI Topical 3% diclofenac in 2.5% hyaluronic acid gel: A review of its use in patients with actinic keratoses.
AU Jarvis B.; Figgitt D.P.
CS D.P. Figgitt, Adis International Inc., 860 Town Center Drive, Langhorne, PA 19407, United States. demail@adis.com
SO American Journal of Clinical Dermatology, (2003) Vol. 4, No. 3, pp. 203-213.
Refs: 44
ISSN: 1175-0561 CODEN: AJCDCI
CY New Zealand
DT Journal; General Review; (Review)
FS 013 Dermatology and Venereology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 24 Apr 2003
Last Updated on STN: 24 Apr 2003

L28 ANSWER 7 OF 14 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI [Perspectives for dermatology in the 21st century].
DERMATOLOGISCHE PERSPEKTIVEN IM 21. JAHRHUNDERT.
AB During the last decades dermatology has been profoundly transformed from its descriptive origin into an important part of modern medicine and biosciences. Areas of interest and expertise in the future will likely be focused on major topics on clinical dermatology (psoriasis, atopic dermatitis, skin infections including those sexually transmitted), dermatologic oncology (squamous cell carcinoma, malignant melanoma), gene technology in biopharmacy and dermatopharmacology, and also the areas dealing with the aging of the skin and its appendages (dermatologic endocrinology, cosmetic dermatology). Increasing knowledge in dermatology is not only relevant for treating skin disease but also for helping our patients to maintain healthy and appealing skin, thus improving their requirements for beautification and their quality of life. While this is an important aim, it should not become our main task. Overall, the perspectives for dermatology are promising; in the end, its further development will depend on how modern societies will recognize its significance and reward its efforts.
AN 2003024430 EMBASE <<LOGINID::20080201>>
TI [Perspectives for dermatology in the 21st century].
DERMATOLOGISCHE PERSPEKTIVEN IM 21. JAHRHUNDERT.
AU Orfanos C.E.
SO Hautarzt, (2002) Vol. 53, No. 9, pp. 596-603.
Refs: 48
ISSN: 0017-8470 CODEN: HAUTAW
CY Germany
DT Journal; General Review; (Review)
FS 013 Dermatology and Venereology
016 Cancer
020 Gerontology and Geriatrics
026 Immunology, Serology and Transplantation

```
     037     Drug Literature Index
LA   German
SL   English; German
ED   Entered STN: 29 Jan 2003
     Last Updated on STN: 29 Jan 2003

L28  ANSWER 9 OF 14  EMBASE  COPYRIGHT (c) 2008 Elsevier B.V. All rights
     reserved on STN
TI   The role of the pharmaceutical industry in drug development in
     dermatology.
AN   2002419122  EMBASE   <<LOGINID::20080201>>
TI   The role of the pharmaceutical industry in drug development in
     dermatology.
AU   Cauwenbergh G.
CS   Dr. G. Cauwenbergh, Barrier Health Technologies, Inc., 1 Stults Dr.,
     Plainsboro, NJ 08536, United States. Flater1@aol.com
SO   Clinics in Dermatology, (Sep 2002) Vol. 20, No. 5, pp. 467-473.
     ISSN: 0738-081X  CODEN: CLDEEU
PUI  S 0738-081X(02)00276-6
CY   United States
DT   Journal; General Review; (Review)
FS   013     Dermatology and Venereology
     036     Health Policy, Economics and Management
     037     Drug Literature Index
     038     Adverse Reactions Titles
     039     Pharmacy
LA   English
ED   Entered STN: 12 Dec 2002
     Last Updated on STN: 12 Dec 2002


=> d his

     (FILE 'HOME' ENTERED AT 16:01:43 ON 01 FEB 2008)

     FILE 'REGISTRY' ENTERED AT 16:02:11 ON 01 FEB 2008
L1             STRUCTURE UPLOADED
L2           0 S L1
L3           2 S L1 SSS FULL
L4           1 S IMIQUIMOD/CN
L5             STRUCTURE UPLOADED
L6           4 S L5
L7          37 S L5 SSS FULL

     FILE 'STNGUIDE' ENTERED AT 16:07:44 ON 01 FEB 2008

     FILE 'HCAPLUS' ENTERED AT 16:09:29 ON 01 FEB 2008
L8         539 S L7
L9        8923 S (FINE LINE) OR WRINKLE
L10          8 S L8 AND L9
L11          5 S L10 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'STNGUIDE' ENTERED AT 16:09:35 ON 01 FEB 2008

     FILE 'HCAPLUS' ENTERED AT 16:09:42 ON 01 FEB 2008

     FILE 'STNGUIDE' ENTERED AT 16:09:43 ON 01 FEB 2008

     FILE 'REGISTRY' ENTERED AT 16:10:56 ON 01 FEB 2008
L12            STRUCTURE UPLOADED
L13          0 S L12
L14          0 S L12 SSS FULL
L15            STRUCTURE UPLOADED
L16          1 S L15
```

```
L17          30 S L15 SSS FULL

     FILE 'CAPLUS' ENTERED AT 16:12:18 ON 01 FEB 2008
L18          45 S L17
L19          19 S L17/THU

     FILE 'STNGUIDE' ENTERED AT 16:12:33 ON 01 FEB 2008

     FILE 'HCAPLUS' ENTERED AT 16:13:16 ON 01 FEB 2008
L20           0 S L9 AND L18
L21           0 S L20 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'STNGUIDE' ENTERED AT 16:13:21 ON 01 FEB 2008

     FILE 'HCAPLUS' ENTERED AT 16:13:43 ON 01 FEB 2008
L22           0 S L18 AND COSMETIC
L23           8 S L18 AND TOPICAL

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 16:32:46 ON 01 FEB 2008
               SEA IMIQUIMOD AND ((FINE LINES) OR WRINKLE OR WRINKLES)
               ---------
                1   FILE ADISINSIGHT
               11   FILE CAPLUS
                3   FILE EMBASE
               22   FILE IFIPAT
                3   FILE PROMT
                1   FILE TOXCENTER
               81   FILE USPATFULL
                3   FILE USPAT2
               12   FILE WPIDS
               12   FILE WPINDEX
L24              QUE IMIQUIMOD AND ((FINE LINES) OR WRINKLE OR WRINKLES)
               ---------
                SEA IMIQUIMOD AND COSMETIC
               ---------
                6   FILE ADISCTI
                1   FILE ADISINSIGHT
                1   FILE ADISNEWS
                9   FILE BIOSIS
                2   FILE BIOTECHNO
                2   FILE CABA
               21   FILE CAPLUS
                8   FILE DDFU
               12   FILE DRUGU
                1   FILE EMBAL
               80   FILE EMBASE
               17   FILE ESBIOBASE
               23   FILE IFIPAT
                4   FILE KOSMET
                1   FILE LIFESCI
               36   FILE MEDLINE
               25   FILE PASCAL
                1   FILE PHIN
               32   FILE PROMT
               32   FILE SCISEARCH
               21   FILE TOXCENTER
              232   FILE USPATFULL
               30   FILE USPAT2
               10   FILE WPIDS
               10   FILE WPINDEX
L25              QUE IMIQUIMOD AND COSMETIC
```

FILE 'EMBASE' ENTERED AT 16:34:49 ON 01 FEB 2008
L26 3 S IMIQUIMOD AND ((FINE LINES) OR WRINKLE OR WRINKLES)
L27 80 S IMIQUIMOD AND COSMETIC
L28 14 S L27 NOT (PY>2003)

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	38.31	819.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.40

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:36:24 ON 01 FEB 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'EMBASE' AT 16:42:56 ON 01 FEB 2008
FILE 'EMBASE' ENTERED AT 16:42:56 ON 01 FEB 2008

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	38.31	819.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.40

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	38.31	819.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.40

FILE 'CAPLUS' ENTERED AT 16:43:05 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Feb 2008 VOL 148 ISS 6
FILE LAST UPDATED: 31 Jan 2008 (20080131/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l19 not l23
48666 TOPICAL
L29 12 L19 NOT L23

=> d l29 1-12 ti abs bib

L29 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Antibody or antigen conjugated with immune response modifier for therapeutic use
AB The present invention provides IRM conjugates that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety in which the covalent link does not depend on UV irradiation The IRM is an imidazoquinoline amine, tetrahydroimidazoquinoline amine, imidazopyridine amine, 1,2-bridged imidazopyridine amine, 6,7-cycloalkylimidazopyridine amine, imidazonaphthyridine amine, tetrahydroimidazonaphthyridine amine, oxazoloquinoline amine, thiazoloquinoline amine, oxazolopyridine amine, thiazolopyridine amine, etc. These IRM compds. appear to act through TLRs to induce selected cytokine biosynthesis and/or co-stimulatory mols. and increase antigen-presenting capacity. The IRM conjugates are directed against e.g. tumor, viral infection, allergy, autoimmune disease ans as vaccine adjuvant.
AN 2007:999273 CAPLUS <<LOGINID::20080201>>
DN 147:321284
TI Antibody or antigen conjugated with immune response modifier for therapeutic use
IN Stoermer, Doris; Griesgraber, George W.; Mendoza, James D.; Bonk, Jason D.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 93pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007100634	A2	20070907	WO 2007-US4673	20070221
	WO 2007100634	A3	20071025		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2006-775468P P 20060222

L29 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Imidazo[4,5-c]quinolin-4-amines as A3 adenosine receptor allosteric modulators, their preparation, pharmaceutical compositions, and use in

therapy

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to 1H-imidazo[4,5-c]quinolin-4-amines of formula I, which are allosteric modulators of A3 adenosine receptors (A3ARs). In compds. I, R1 is selected from (un)substituted aryl, (un)substituted aralkyl, or (un)substituted aryl fused to a cycloalkyl or cycloalkenyl, optionally comprising one or more heteroatoms; and R2 is selected from H, C1-10 alkyl, C1-10 alkoxy, C2-10 alkenyl, C2-10 alkynyl, C4-10 cycloalkyl, 5- to 7-membered heteroaryl, etc. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I as active ingredient, as well as to the use of the compns. for the treatment of conditions responding to A3AR modulation, such as malignancy, immuno-compromised affliction, or a condition associated with high intraocular pressure. Dimerization of nitromethane, condensation with anthranilic acid, and heterocyclization gave 3-nitro-4-hydroxyquinoline, which underwent chlorination, amination, hydrogenation, and heterocyclization with cyclohexanecarboxylic acid to give II. N-Oxidation of II followed by chlorination and substitution with 3,4-dichloroaniline resulted in the formation of imidazo[4,5-c]quinolin-4-amine III. The effects of the compds. of the invention were tested at all four adenosine receptor subtypes together with their effects on the allosteric site on the human adenosine A3 receptor. The best separation between orthosteric and allosteric recognition was found with compound III.

AN 2007:873387 CAPLUS <<LOGINID::20080201>>

DN 147:235172

TI Imidazo[4,5-c]quinolin-4-amines as A3 adenosine receptor allosteric modulators, their preparation, pharmaceutical compositions, and use in therapy

IN Goblyos, Aniko; Brussee, Johannes; Ijzerman, Adriaan P.; Gao, Zhan-Guo; Jacobson, Kenneth

PA The Government of the U.S.A., Rep. by the Sec., Dept. Of Health and Human Services, USA; Universiteit Leiden

SO PCT Int. Appl., 60pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007089507	A1	20070809	WO 2007-US1930	20070125

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2006-762141P P 20060126

OS MARPAT 147:235172

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 12 CAPLUS

TI Adjuvant for DNA vaccines for treating breast cancer
AB The disclosed invention provides a DNA vaccine useful for treating breast cancer. Generally, the vaccine includes an expression vector that encodes a clin. relevant breast cancer-associated antigenic peptide and an immune response modifier (IRM) compound as an adjuvant, specifically, a TLR8 receptor-selective agonist. The IRM compound comprises an imidazoquinoline amine or a thiazoloquinoline amine.
AN 2006:363584 CAPLUS <<LOGINID::20080201>>
DN 144:389108
TI Adjuvant for DNA vaccines for treating breast cancer
IN Miller, Richard L.; Provinciali, Mauro; Smorlesi, Arianna
PA 3M Innovative Properties Co., USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006042254	A2	20060420	WO 2005-US36594	20051007
	WO 2006042254	A3	20061109		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1804583	A2	20070711	EP 2005-818574	20051007
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	US 2007243215	A1	20071018	US 2007-576312	20070329
PRAI	US 2004-617014P	P	20041008		
	US 2005-688540P	P	20050608		
	WO 2005-US36594	W	20051007		

L29 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Immune response modifiers for enhancing vaccination against HIV
AB The authors disclose methods of eliciting an immune response against HIV. Generally, the method includes administering to a subject an effective amount of an immune response modifier (IRM)-HIV composition that includes an IRM
portion paired with an HIV antigen. In one example, the immune response modifiers are purine derivs.
AN 2006:187309 CAPLUS <<LOGINID::20080201>>
DN 144:252591
TI Immune response modifiers for enhancing vaccination against HIV
IN Kedl, Ross M.
PA USA
SO U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006045886	A1	20060302	US 2005-213405	20050826
	WO 2006026470	A2	20060309	WO 2005-US30482	20050826
	WO 2006026470	A3	20060406		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1786450 A2 20070523 EP 2005-791412 20050826
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRAI US 2004-604903P P 20040827
WO 2005-US30482 W 20050826

L29 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Immune response modifiers for enhancing vaccination against HIV
AB The authors disclose methods of eliciting an immune response against HIV. Generally, the method includes administering to a subject an effective amount of an immune response modifier (IRM)-HIV composition that includes an IRM
portion paired with an HIV antigen. In one example, the immune response modifiers are purine derivs.
AN 2006:187218 CAPLUS <<LOGINID::20080201>>
DN 144:252590
TI Immune response modifiers for enhancing vaccination against HIV
IN Kedl, Ross M.; Seder, Robert A.
PA USA
SO U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006045885	A1	20060302	US 2005-213354	20050826
WO 2006026394	A2	20060309	WO 2005-US30340	20050826
WO 2006026394	A3	20080117		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1799256 A2 20070627 EP 2005-792500 20050826
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

PRAI US 2004-605187P P 20040827
WO 2005-US30340 W 20050826

L29 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Compositions and methods for induction of opioid receptors, and therapeutic use
AB The invention provides compns. and method for increasing expression of

opioid receptors. Generally, the compns. include an opioid receptor-inducing compound (e.g. an imidazoquinoline amine compound) and, optionally, an opioid receptor ligand. Generally, the methods include contacting a cell with an amount of an opioid receptor-inducing compound effective for inducing expression of the opioid receptor and, optionally, contacting the cell with an opioid receptor ligand. The methods of the invention may be used e.g. to reduce the effects of tissue damage.

AN 2004:905622 CAPLUS <<LOGINID::20080201>>
DN 141:374755
TI Compositions and methods for induction of opioid receptors, and therapeutic use
IN Birmachu, Woubalem M. R.; Slade, Herbert B.; Stolpa, John C.; Urosevic, Mirjana
PA 3M Innovative Properties Company, USA
SO U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004214851	A1	20041028	US 2004-832737	20040427
	WO 2004096144	A2	20041111	WO 2004-US12897	20040427
	WO 2004096144	A3	20050909		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1617845	A2	20060125	EP 2004-760404	20040427
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-466227P	P	20030428		
	WO 2004-US12897	W	20040427		

L29 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Vaccines comprising TLR agonist, TNF/TNF receptor agonist and antigen for inducing cellular immune response against infection or tumor
AB The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist, a TNF or TNF receptor agonist and an tumor antigen or viral, bacterial or parasitic antigen. The TLR agonist is an agonist of TLR1-10 e.g. IRM compound, MALP-2, LPS, polyIC, CpG or any combination. The TNF agonist is an agonist or antibody against CD40L, OX40 ligand, 4-1BB ligand, CD27, CD30 ligand, TNF-α, TNF-β, RANK ligand, LT-α, LT-β, GITR ligand or LIGHT. The TNF receptor agonist is an antibody or agonist of CD40, OX40, 4-1BB, CD27 ligand, CD30, TNFR2, RANK, LT-αR, LT-βR, HVEM, GITR, TROY or RELT. These immunostimulatory combinations are useful for inducing Th1 immune response or antigen-specific CD8+ effector and memory T cell response against infectious and neoplastic conditions.
AN 2004:589386 CAPLUS <<LOGINID::20080201>>
DN 141:139130
TI Vaccines comprising TLR agonist, TNF/TNF receptor agonist and antigen for inducing cellular immune response against infection or tumor
IN Noelle, Randolph J.; Ahonen, Cory L.; Kedl, Ross M.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004060319	A2	20040722	WO 2003-US41796	20031230
	WO 2004060319	A3	20041104		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2511538	A1	20040722	CA 2003-2511538	20031230
	US 2004141950	A1	20040722	US 2003-748010	20031230
	AU 2003300184	A1	20040729	AU 2003-300184	20031230
	EP 1578419	A2	20050928	EP 2003-800433	20031230
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006512391	T	20060413	JP 2004-564947	20031230
PRAI	US 2002-437398P	P	20021230		
	WO 2003-US41796	W	20031230		

L29 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods and products for enhancing immune responses using imidazoquinoline compounds in combination with modified immunostimulatory oligonucleotide
AB The invention involves administration of an imidazoquinoline agent in combination with another therapeutic agent. The combination of drugs may be administered in synergistic amts. or in various dosages or at various time schedules. The invention also relates to kits and compns. concerning the combination of drugs. The combinations can be used to enhance ADCC, stimulate immune responses and/or patient and treat certain disorders. Specifically, the imidazoquinoline compns. R-848 is used which is shown to be more potent inducer of proinflammatory cytokines NF-κB in 293T cells by reconstitution of TLR9 signaling through co-transfecting TLR9, TLR8 and TLR7 into 293T cell. Furthermore, CpG oligonucleotides (ODNs, in particular, CpG ODN #7909) and R-848 are tested either together or individually for their ability to augment a cytolytic T lymphocyte response against antigen (e.g., HBsAg) in vivo using mouse model. The combination of R-848 and CpG ODN together is shown to result in an additive effect; while no augmentation of the CTL response over antigen alone is observed using control ODN either alone or with R-848. The distribution of antibody isotype also shows CpG ODN produces higher levels of IgG2a antibodies regardless of whether R-848 is present, and R-848 appears to increase the level of IgG2a and decrease the level of IgG1 as compared to the antigen alone response.
AN 2003:570637 CAPLUS <<LOGINID::20080201>>
DN 139:132442
TI Methods and products for enhancing immune responses using imidazoquinoline compounds in combination with modified immunostimulatory oligonucleotide
IN Krieg, Arthur M.; Schetter, Christian; Bratzler, Robert L.; Vollmer, Jorg; Jurk, Marion; Bauer, Stefan
PA University of Iowa Research Foundation, USA
SO U.S. Pat. Appl. Publ., 112 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	US 2003139364	A1	20030724	US 2002-272502	20021015
	AU 2002360278	A1	20031111	AU 2002-360278	20021015
	CA 2462203	A1	20031120	CA 2002-2462203	20021015
	WO 2003094836	A2	20031120	WO 2002-US33051	20021015
	WO 2003094836	A3	20040923		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1478371	A2	20041124	EP 2002-795524	20021015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005519990	T	20050707	JP 2004-502925	20021015
	US 2006188913	A1	20060824	US 2006-368334	20060303
PRAI	US 2001-329208P	P	20011012		
	US 2002-272502	A1	20021015		
	WO 2002-US33051	W	20021015		

L29 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists

AB We present a combined computational study aimed at identifying the three-dimensional structural properties required for different classes of compds. to show antagonistic activity toward the A1 adenosine receptor (AR). Particularly, an approach combining pharmacophore mapping, mol. alignment, and pseudoreceptor generation was applied to derive a hypothesis of the interaction pathway between a set of A1 AR antagonists taken from the literature and a model of the putative A1 receptor. The pharmacophore model consists of seven features and represents an improvement of the N6-C8 model, generally reported as the most probable pharmacophore model for A1 AR agonists and antagonists. It was used to build up a pseudoreceptor model able to rationalize the relationships between structural properties and biol. data of, and external to, the training set. In fact, to further assess its statistical significance and predictive power, the pseudoreceptor was employed to predict the free energy of binding associated with compds. constituting a test set. While part of these mols. was also taken from the literature, the remaining compds. were designed and synthesized by our research group. All of the new compds. were tested for their affinity toward A1, A2a, and A3 AR, showing interesting antagonistic activity and A1 selectivity.

AN 2002:720128 CAPLUS <<LOGINID::20080201>>

DN 137:379680

TI Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists

AU Bondavalli, Francesco; Botta, Maurizio; Bruno, Olga; Ciacci, Andrea; Corelli, Federico; Fossa, Paola; Lucacchini, Antonio; Manetti, Fabrizio; Martini, Claudia; Menozzi, Giulia; Mosti, Luisa; Ranise, Angelo; Schenone, Silvia; Tafi, Andrea; Trincavelli, Maria Letizia

CS Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Genoa, I-16132, Italy

SO Journal of Medicinal Chemistry (2002), 45(22), 4875-4887
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 137:379680

RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives
AB We have identified a series of 1H-imidazo-[4,5-c]quinolines as selective allosteric enhancers of human A3 adenosine receptors. Several of these compds. potentiated both the potency and maximal efficacy of agonist-induced responses and selectively decreased the dissociation of the agonist N6-(4-amino-3-[125I]iodobenzyl) -5'-N-methylcarboxamidoadenosine from human A3 adenosine receptors. There was no effect on the dissociation of the antagonist [3H]8-ethyl-4-methyl-2-phenyl- (8R)-4,5,7,8-tetrahydro-1H-imidazo[2.1-i]purin-5-one (PSB-11) from the A3 receptors, as well as [3H]N6-[(R)-phenylisopropyl]adenosine from rat brain A1 receptors and [3H]2-[p-(2-carboxyethyl)phenyl-ethylamino] -5'-N-ethylcarboxamidoadenosine from rat striatal A2A receptors, suggesting the selective enhancement of agonist binding at A3 receptors. The analogs were tested as antagonists of competitive binding at human A3 receptors, and Ki values ranging from 120 nM to 101 μM were observed; as for many allosteric modulators of G protein-coupled receptors, an ortho-steric effect was also present. The most promising leads from the present set of analogs seem to be the 2-cyclopentyl-1H-imidazo[4,5-c]quinoline derivs., of which the 4-phenylamino analog DU124183 had the most favorable degree of allosteric modulation vs. receptor antagonism. The inhibition of forskolin-stimulated cAMP accumulation in intact cells that express human A3 receptors was employed as a functional index of A3 receptor activation. The enhancer DU124183 caused a marked leftward shift of the concentration-response curve of the A3 receptor agonists in the presence of antagonist and, surprisingly, a potentiation of the maximum agonist efficacy by approx. 30%. Thus, we have identified a novel structural lead for developing allosteric enhancers of A3 adenosine receptors; such enhancers may be useful for treating brain ischemia and other hypoxic conditions.
AN 2002:526972 CAPLUS <<LOGINID::20080201>>
DN 138:130578
TI Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives
AU Gao, Zhan-Guo; Kim, Seong Gon; Soltysiak, Kelly A.; Melman, Neli; IJzerman, Adriaan P.; Jacobson, Kenneth A.
CS Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
SO Molecular Pharmacology (2002), 62(1), 81-89
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of nucleoside uronamides as A3 adenosine receptor agonists
GI



I

AB The present invention provides N6-benzyladenosine-5'-N-uronamide and related substituted compds. I (R1 = amide; R2 = halo, amino, alkenyl, alkynyl, thio, alkylthio; R3 = S-1-phenylethyl, Bn, phenylethyl), particularly those containing substituents on the benzyl and/or uronamide groups, and modified xanthine ribosides, as well as pharmaceutical compns. containing such compds. The present invention also provides a method of selectively activating an A3 adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A3 adenosine receptor a therapeutically effective amount of a compound which binds with the A3 receptor so as to stimulate an A3 receptor-dependent response. Thus, N6-(3-iodobenzyl)adenosine was prepared tested for its affinity in binding at rat brain A1, A2, A3 adenosine receptors (Ki = 9.5-220.0 nM).

AN 1998:441960 CAPLUS <<LOGINID::20080201>>

DN 129:109311

TI Preparation of nucleoside uronamides as A3 adenosine receptor agonists

IN Jacobson, Kenneth A.; Gallo-Rodriguez, Carola; Van Galen, Philip J. M.; Von Lubitz, Dag K. J. E.; Jeong, Heaok Kim

PA United States Dept. of Health and Human Services, USA

SO U.S., 54 pp., Cont.-in-part of U. S. Ser. No. 163,324, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5773423	A	19980630	US 1994-274628	19940713
	US 5688774	A	19971118	US 1995-396111	19950228
PRAI	US 1993-91109	B2	19930713		
	US 1993-163324	B2	19931206		
	US 1994-274628	A2	19940713		

OS MARPAT 129:109311

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of 1H-imidazo[4,5-c]quinolin-4-amines as antiviral agents

GI



I

AB Title compds. I (R = C1-4 alkoxy, C1-4 alkyl, halo; n = 0-2; R2 = H, C1-4 alkyl, (substituted) Ph, PhCH2, PhCH2CH2) or a salt thereof, useful as antiviral agents and method for interferon induction (no data), are prepared 4-Chloro-β,β-dimethyl-2-(phenylmethyl)-1H-imidazo[4,5-c]quinoline-1-ethanol (preparation given) was aminated to give I(Rn = H; R2 = PhCH2).

AN 1991:122367 CAPLUS <<LOGINID::20080201>>

DN 114:122367

TI Preparation of 1H-imidazo[4,5-c]quinolin-4-amines as antiviral agents

IN Gerster, John F.

PA Riker Laboratories, Inc., USA

SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 385630	A2	19900905	EP 1990-301766	19900219
	EP 385630	A3	19920102		
	EP 385630	B1	19961127		
	R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	ES 2094141	T3	19970116	ES 1990-301766	19900219
	CA 2010430	A1	19900827	CA 1990-2010430	19900220
	AU 9050054	A	19900830	AU 1990-50054	19900222
	AU 630921	B2	19921112		
	KR 179992	B1	19990320	KR 1990-2521	19900226
	JP 03027380	A	19910205	JP 1990-47117	19900227
	JP 2941336	B2	19990825		
	US 5756747	A	19980526	US 1995-455273	19950531
PRAI	US 1989-316035	A	19890227		
	US 1993-70262	A1	19930602		

OS MARPAT 114:122367